Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study - sprookjes - yvandenbroek - TriplyDB

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

http://www.wikidata.org/entity/Q28282827

about

Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)The European Hematology Association Roadmap for European Hematology Research: a consensus document Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006.Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.Gastric malt lymphoma: Analysis of a series of consecutive patients over 20 years.Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas Mucosa-associated lymphoid tissue lymphoma with unusual 18F-FDG hypermetabolism arising at the colorectal anastomosis.Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: recent progress in pathogenesis and management Chlorambucil-induced acute interstitial pneumonitis.Clinical aspects of malt lymphomas.Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: A case report and literature review.Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG).Survival of patients with gastric lymphoma in Germany and in the United States.Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease.High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.Histologic transformation in marginal zone lymphomas†.Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years.Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012.Bulky pulmonary mucosa-associated lymphoid tissue lymphoma treated with yttrium-90 ibritumomab tiuxetan.Ectopic Anterior Mediastinal Pathology in the Chest: Radiologic-pathologic Correlation of Unexpected Encounters with the "Terrible Ts".Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study

P2860

Q26741090-BE7CC033-FC40-43F5-858B-A8A8A8524549 Q26771654-0374D4F4-4FCC-4D01-8A46-9CA941CD21C4 Q26799731-19297E8E-4981-414F-9875-385F760281D8 Q28296146-0914DE1D-532E-4D60-8F40-9195C053C984 Q28830861-A768E596-CE99-4752-A43D-293608DCA620 Q30249335-D2F8C5A6-4652-4560-8EBA-CF243F59DBCF Q30895580-878E4D32-FABB-4D9E-92C8-AB88E9CECD15 Q33414243-1856C0FC-27EA-41EA-A437-ACC5B2117155 Q33418199-4F16F4EA-20CC-4C16-B062-42DBA79C5E29 Q33587826-F7669BD0-E257-4F13-9E96-A9F483521D1F Q33639281-366EA53D-D899-4BF9-B36F-53D18C03A360 Q36116349-E7283617-E592-4B80-880D-4F439A43A3EB Q36768594-B7EE5746-4F02-4ED1-85F9-53D091940C9B Q37045745-A13A45BF-2109-4A2F-973E-F295BE2323B5 Q37578581-BB6699CE-6B30-4256-8C4E-B8BDFC238725 Q37624527-5ABEEDD0-869E-40C7-A7B3-BFAAC0EF5BF0 Q38096425-6FD28882-1168-4999-A159-2A3269068DFE Q38173350-0F9DD47D-C614-454B-A39E-C1563822E53E Q38202645-9259A235-EDC4-4411-85E6-8693D2380A93 Q38252813-A6AD5628-400F-4E73-857C-B1610EB27EAE Q38260354-D451909B-A290-41F4-AD86-3DA121848D1D Q38465823-87533B01-4857-41DC-9917-5DBC42E1B6B9 Q38544142-E290A7FD-CFCE-4A08-B48D-C86013BDEA62 Q38574045-F5B9F9DD-C896-412E-9859-DC526D2F4D2E Q38612199-83702FB9-00B6-4B18-8166-802A6347B247 Q38673151-24B06365-D380-496C-8C9A-EB20B9A9A114 Q38711166-1515E567-7D83-4B53-95A1-F5B591F57A9F Q39206620-0AE9938E-254D-46F3-B6D1-BCBED2A6EC2F Q39215476-34E627BD-7228-44D8-AAE6-E7271B16C7DF Q40308641-D4CDD042-6F90-4A5A-AFE3-00E6F83A1D94 Q40760313-BFFB9227-CFE9-455E-94D4-02CA52FF1DA8 Q40946968-6DC3AE5D-3376-4825-9FDF-15D44EA1463E Q41197838-B38D0D62-01F0-40ED-9E4B-69243AB1CCE0 Q41263804-B0A85309-2664-4F57-B8D8-20CFC1B4F81B Q41326723-ACDB9A86-FB17-47D2-B467-48F185302716 Q41511282-008EE7C7-1C83-46F1-91AD-53B1A88F8BC5 Q41681723-6C555B65-0B32-464E-A042-C06EE0F9B7B8 Q41962813-8E493E21-6C08-4855-9594-26B220C21B3C Q42019754-831E6EBD-99D2-4AFD-BBD1-EF001DDD3938 Q42366631-47A7D6CE-00B6-4D6C-8B4F-3AE3BCE3AD82

P2860

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

http://www.wikidata.org/entity/Q28282827

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@ast

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@en

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@nl

type

label

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@ast

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@en

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@nl

prefLabel

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@ast

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@en

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@nl

P1433

Q28282827-F479A09C-A4CF-46FB-A8EE-47DF631D2DE2

P1476

Q28282827-F9C84CA9-3DE7-483B-ABB8-EC435D7D02D5

P2093

Q28282827-0923C26B-0D19-4AE8-B273-0B1E4B50C4DA

Q28282827-0F0D4E15-A3BD-4C4A-8AA2-6C80B56619F6

Q28282827-14720C5E-1B95-4CB4-912E-EEA97E4F5CDE

Q28282827-48F06584-5761-4D78-BDA0-D28021CAE10F

Q28282827-48FAD5B8-AA60-4D46-8B31-3A992BF218CB

Q28282827-99AAD04F-A8F1-4604-BBBF-1DC6A8A42395

Q28282827-9A68ABC6-8A48-424C-9EA9-BAF509714556

Q28282827-9B2EC13C-18FA-4487-869E-5A07D367AB7D

Q28282827-A322BD15-A991-40B3-8A96-44413818106E

Q28282827-B78158BE-2D22-4ECE-A1E0-1B58DFD8CEF0

P304

Q28282827-FF355811-2D3C-4FDF-9366-7430A77FC46D

P31

Q28282827-370BA507-0A78-4FEC-83C7-A054E3E1AEE1

P3181

Q28282827-73D27F71-9FDC-4DBF-BFC1-33C663412E0E

P356

Q28282827-9B095992-4F1B-47BF-B7BD-CA500B121E84

P407

Q28282827-1EFFC208-1949-434D-B74A-AB0872C9347F

P433

Q28282827-28655814-5D34-4C11-A138-40BCA1B7585C

P478

Q28282827-B43FA739-C569-4076-91B0-DB81932C70D8

P50

Q28282827-1A5A7039-C5F2-4C11-89D9-4B2E08D22558

Q28282827-2141884B-043A-4F3E-A1A7-9C10318AB140

Q28282827-2CE58CA0-70CE-43A8-8C65-474C333200EF

Q28282827-42D44D8E-4C6F-4CB5-BD06-99A3A0ED5BBF

Q28282827-BE1614F9-570B-4F01-814F-E990E6D54053

Q28282827-BE8EB03C-CBD2-4798-A3B0-5E209F01C906

Q28282827-C259CC5B-FAD4-4D1F-B40D-A8F04D88F316

P577

Q28282827-9D13B0C6-57C6-4BCB-87EF-77A34BAE3AE4

P698

Q28282827-75F76CCB-19CF-4E72-B4CE-AC42013DCB83

P921

Q28282827-0425427E-8E46-4665-AB96-E1BFBE5E85C2

Q28282827-6E55AFFB-0D30-4B8B-AE2A-18E3A2748ED2

P3181

P356

JCO.2011.40.6272

P1433

Journal of Clinical Oncology

P1476

Addition of rituximab to chlor ...... the IELSG-19 Randomized Study

@en

P2093

Andrew Jack

http://www.w3.org/2001/XMLSchema#string

Annarita Conconi

http://www.w3.org/2001/XMLSchema#string

Armando López-Guillermo

http://www.w3.org/2001/XMLSchema#string

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

Catherine Sebban

http://www.w3.org/2001/XMLSchema#string

Catherine Thieblemont

http://www.w3.org/2001/XMLSchema#string

Daniele Laszlo

http://www.w3.org/2001/XMLSchema#string

Fabrice Jardin

http://www.w3.org/2001/XMLSchema#string

Franck Morschhauser

http://www.w3.org/2001/XMLSchema#string

Franco Cavalli

http://www.w3.org/2001/XMLSchema#string

P304

565-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4279976

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2011.40.6272

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Christiane Copie-Bergman

Catherine Thieblemont

Peter W Johnson

Giovanni Martinelli

P577

2013-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23295789

http://www.w3.org/2001/XMLSchema#string

P921

chlorambucilddv